Company Active LTD

Company profile

Orthoplastics Limited

Loading...

Orthoplastics Limited is a UK company with status active founded in 2005 based in North West England.

CRN
05616266
Founded
2005
Age
20

Overview

Legal name
ORTHOPLASTICS LIMITED
Region
North West England
Registered address
GROVE MILL
TODMORDEN ROAD
BACUP
LANCASHIRE
OL13 9EF
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

10 events
06 Nov
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

29 Sep
2026

Accounts due

Accounts Due

Next accounts due date

07 Apr
2026

Termination Secretary Company With Name Termination Date

Officers

TM02 | Transaction MzUxNDc1NzQ0NGFkaXF6a2N4

Published 07 Apr 2026 13:31

23 Oct
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

25 Feb
2025

Change Person Director Company With Change Date

Officers

CH01 | Transaction MzQ1NjM1NzUwMGFkaXF6a2N4

Published 25 Feb 2025 16:10

20 Feb
2025

Appoint Person Director Company With Name Date

Officers

AP01 | Transaction MzQ1NTgzODY2NWFkaXF6a2N4

Published 20 Feb 2025 03:18

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

11 Nov
2024

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzQ0MjYzOTg4OWFkaXF6a2N4

Published 11 Nov 2024 12:39

27 Sep
2024

Change Account Reference Date Company Previous Shortened

Accounts Awaiting analysis

AA01 | Transaction MzQzNzUxMzcwN2FkaXF6a2N4

Published 27 Sep 2024 11:10

08 Nov
2005

Incorporated

Inception

Company registered at Companies House

Public funding

1 award
First funded
2022
Funded years
2022
Age at first award
16 years

Projects

2022 Collaborative R&D

Bone Regenerating Knee Implants for Long Term Bone Health

1 Jun 2022 to 31 May 2024

Awarded
£0
Total cost £132,000

The NHS performs 130,000 knee replacements annually. Demand is growing due to our ageing population and backlog caused by Covid-19\. Partial knee surgery is the fastest growing treatment, particularly in young patients for whom the risk of becoming less active, productive and socially connected is higher and has more severe long term consequences. Despite...

Product types

Collaborative R&D